The article presents the authors' views on the economics of pricing pharmaceutical treatments and medical devices based on indication of their utilization. They explain the varied responses to a treatment with the type of tumor and biomarkers of disease. The authors thinks that proliferation of precision medicine for genomic, proteomic, and structural biomarkers of identified patients will have greater treatment benefits.
Chandra, Amitabh, and Craig Garthwaite. "The Economics of Indication-Based Drug Pricing." New England Journal of Medicine 377.2 (July 2017): 103-106.